tailieunhanh - Báo cáo y học: "Atorvastatin pretreatment diminishes the levels of myocardial ischemia markers early after CABG operation: an observational study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Atorvastatin pretreatment diminishes the levels of myocardial ischemia markers early after CABG operation: an observational study | Ege et al. Journal of Cardiothoracic Surgery 2010 5 60 http content 5 1 60 JOTS JOURNAL OF CARDIOTHORACIC SURGERY RESEARCH ARTICLE Open Access Atorvastatin pretreatment diminishes the levels of myocardial ischemia markers early after CABG operation an observational study 1 2 3 1 Erdal Ege Yuksel Dereli Sevil Kurban Ali Sarigul Abstract Background Statin pretreatment has been associated with a decrease in myocardial ischemia markers after various procedures and cardiovascular events. This study examined the potential beneficial effects of preoperative atorvastatin treatment among patients undergoing on-pump CABG operation. Methods Twenty patients that had received atorvastatin treatment for at least 15 days prior to the operation and 20 patients who had not received any antihyperlipidemic agent prior to surgery were included in this study. CK-MB and troponin I levels were measured at baseline and 24 hours after the operation. Perioperative variables were also recorded. Results Twenty-four hours after the operation troponin I and CK-MB levels were significantly lower in the atorvastatin group for CK-MB levels versus ng ml p for troponin I levels versus ng ml p . In addition atorvastatin use was associated with a decrease in the duration of ICU stay. Conclusions Preoperative atorvastatin treatment results in significant reductions in the levels of myocardial injury markers early after on-pump CABG operation suggesting a reduction in perioperative ischemia in this group of patients. Further studies are needed to elucidate the mechanisms of these potential benefits of statin pretreatment. Background Ambulatory use of 3-hydroxy-3-methylglutaryl-CoA HMG-CoA reductase inhibitors or statins is known to reduce the risk of cardiovascular events including death myocardial infarction stroke and renal function in addition to their lowering effect on low-density lipoprotein LDL and total cholesterol levels

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.